SCHEMBL25366122

SCHEMBL25366122

CC(=O)N1C(=S)NC(=O)C1CCc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
HDAC2 Q92769 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
LMNA P02545 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MTNR1B P49286 1/20 0.40
HSD17B10 Q99714 1/20 0.39
ATM Q13315 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
POLB P06746 1/20 0.37
BRD4 O60885 1/20 0.36
GFER P55789 1/20 0.36
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25363327 0.76 BRD4 (0.42) ALDH1A1SMN1; SMN2MEN1KMT2APOLB
SCHEMBL25367130 0.76 KMT2A (0.41) ALDH1A1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL25366343 0.76 NPC1 (0.38) ALDH1A1MEN1KMT2AGFER
SCHEMBL25367134 0.76 KMT2A (0.41) ALDH1A1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL25366861 0.75 ALDH1A1 (0.38) ALDH1A1HDAC6LMNASMN1; SMN2HSD17B10
SCHEMBL25366849 0.75 HSD17B10 (0.46) ALDH1A1HDAC2HDAC8HDAC6LMNA
SCHEMBL25368673 0.75 HPGD (0.43) ALDH1A1LMNAHSD17B10MEN1KMT2A
SCHEMBL25367741 0.74 MEN1 (0.42) ALDH1A1LMNAHSD17B10MEN1KMT2A
SCHEMBL25367152 0.74 NPSR1 (0.46) ALDH1A1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL25366772 0.72 ALDH1A1 (0.41) ALDH1A1LMNASMN1; SMN2HSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018125-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS ERMIUM THERAPEUTICS (FR) 2024-01-18 US disclosed
CN-116568675-A Cyclic isothiourea derivatives as CXCR4 modulators 埃尔米乌治疗公司 2023-08-08 CN disclosed
EP-4217353-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS Ermium Therapeutics (FR) 2023-08-02 EP disclosed
WO-2022064075-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS ERMIUM THERAPEUTICS (FR) 2022-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018125-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS CXCR4, CXCR1, CXCL12 ALDH1A1 2260/4885HDAC2 634/4885HDAC8 697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.